A Study to Compare PK Characteristics and Safety Profiles Between AD-228B and AD-2284

Addpharma

Status and phase: Enrolling; Phase 1

Conditions: Primary Hypercholesterolaemia

Treatments: Drug: AD-228B; Drug: AD-2284

Study type: Interventional

Funder types: Industry

Identifiers

NCT06884098

AD-228BE-H

Details and patient eligibility

About

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-228B in healthy subjects.

Enrollment: 60 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body weight equal to or greater than 50kg (Female 45kg) and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
• The Age equal to or greater than 19 in healthy volunteers at the time of screening visit

Exclusion criteria

• Participation in other clinical study with an investigational drug within the 6 months from scheduled first administration
• Other exclusions applied

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Sequence A (RT)

Experimental group

Description:

Period 1: Reference Drug (AD-2284), Period 2: Test Drug (AD-228B)

Treatment:

Drug: AD-2284

Drug: AD-228B

Sequence B (TR)

Experimental group

Description:

Period 1: Test Drug (AD-228B), Period 2: Reference Drug (AD-2284)

Treatment:

Drug: AD-2284

Drug: AD-228B